BRPI0618469A2 - hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto - Google Patents

hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto Download PDF

Info

Publication number
BRPI0618469A2
BRPI0618469A2 BRPI0618469-3A BRPI0618469A BRPI0618469A2 BR PI0618469 A2 BRPI0618469 A2 BR PI0618469A2 BR PI0618469 A BRPI0618469 A BR PI0618469A BR PI0618469 A2 BRPI0618469 A2 BR PI0618469A2
Authority
BR
Brazil
Prior art keywords
bone
parathyroid hormone
black bear
methods
bear parathyroid
Prior art date
Application number
BRPI0618469-3A
Other languages
English (en)
Inventor
Seth W Donahue
Original Assignee
Univ Michigan Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Tech filed Critical Univ Michigan Tech
Publication of BRPI0618469A2 publication Critical patent/BRPI0618469A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/37—Parathyroid hormone [PTH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

HORMÈNIO PARATIRóIDE DE URSO PRETO E MéTODOS DE USO DE HORMÈNIO PARATIRóIDE DE URSO PRETO. O hormónio paratirólde de urso preto (PTH) e fragmentos funcionais são fornecidos aqui. Também fornecidos são métodos de usar PTH de urso preto e fragmentos funcionais para aumentar cAMP em uma célula de formação de osso; reduzir apoptose em uma célula de formação de osso; diminuir a relação de níveis de expressão de proteína Bax para proteína Bc1-2 em uma célula de formação de osso; aumentar o nível de expressão de uma ou mais de uma proteína de matriz de osso, um ativador transcricional, ou um regulador transcricional em uma célula de formação de osso; realçar a densidade mineral do osso, aumentar a massa óssea, diminuir a perda óssea, ou reduzir a incidência de fraturas de osso, ou qualquer combinação destes, em um indivíduo; também fornecidos são anticorpos voltados contra hormónio de paratíróide (PTH) preto urso e fragmentos funcionais destes.
BRPI0618469-3A 2005-11-10 2006-11-13 hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto BRPI0618469A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73614505P 2005-11-10 2005-11-10
PCT/US2006/060844 WO2007059470A2 (en) 2005-11-10 2006-11-13 Black bear parathyroid hormone and methods of using black bear parathyroid hormone

Publications (1)

Publication Number Publication Date
BRPI0618469A2 true BRPI0618469A2 (pt) 2011-08-30

Family

ID=38049379

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618469-3A BRPI0618469A2 (pt) 2005-11-10 2006-11-13 hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto

Country Status (9)

Country Link
US (1) US7994129B2 (pt)
EP (1) EP1945245A2 (pt)
JP (1) JP2009515535A (pt)
CN (1) CN101355959B (pt)
AU (1) AU2006315132A1 (pt)
BR (1) BRPI0618469A2 (pt)
CA (1) CA2628945A1 (pt)
IL (1) IL191250A0 (pt)
WO (1) WO2007059470A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509996A1 (en) * 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4822609A (en) 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812304A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US5420242A (en) 1986-10-22 1995-05-30 Kaare M. Gautvik Production of human parathyroid hormone from microorganisms
US5457092A (en) 1987-07-30 1995-10-10 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Methods of promoting bone growth in mammals comprising administration of modified parathyroid hormone
EP0341963A3 (en) 1988-05-09 1991-07-24 Merck & Co. Inc. Parathyroid hormone antagonists
US5744444A (en) 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
GB9020544D0 (en) 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
DE69125394T2 (de) 1990-11-26 1997-08-21 Robert R. Omaha Nebr. Recker Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
WO1993006846A1 (en) 1991-10-10 1993-04-15 Pang Peter K T Parathyroid hormone analogues and use in osteoporosis treatment
US5317010A (en) 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
SK74594A3 (en) 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
DE4203040A1 (de) 1992-02-04 1993-08-05 Boehringer Mannheim Gmbh Neue parathormonfragmente, deren herstellung und diese enthaltende arzneimittel
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
JPH08503692A (ja) 1992-08-05 1996-04-23 アール． ヒリカー，サンドラ 上皮小体ホルモン断片及びアナログ
BR9307141A (pt) 1992-09-29 1999-03-30 Inhale Therapeutic Syst Processo para a liberação sistência pulsátil de um fragmento ativo de hormônio de paratiróide (PTH) para um hospedeiro mamífero e para um paciente e composição farmacêutica
US6855337B1 (en) 1993-06-17 2005-02-15 Carle Development Foundation Bear derived isolate and method
WO1995002610A1 (en) 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
TW303299B (pt) 1993-07-22 1997-04-21 Lilly Co Eli
US5496801A (en) 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US6110892A (en) 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5955425A (en) 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO1996007418A1 (en) 1994-09-09 1996-03-14 The Procter & Gamble Company Phosphonates and parathyroid hormone for osteoporosis
AU686458B2 (en) 1994-09-09 1998-02-05 Procter & Gamble Company, The Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
CA2199250A1 (en) 1994-09-09 1996-03-14 John Althorp Bevan Estrogens and parathyroid hormone for treating osteoporosis
EP0800405A4 (en) 1994-12-19 1998-11-11 Beth Israel Hospital CONTINUOUS ADMINISTRATION OF LOW DOSES OF HORMONE PARATHYRO DIENNE OR ITS AGONIST
US5747456A (en) 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
ATE238043T1 (de) 1994-12-22 2003-05-15 Astrazeneca Ab Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
CA2178894A1 (en) 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
JP2001517957A (ja) 1997-05-14 2001-10-09 アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド ペプチド副甲状腺ホルモン類縁体
US20020136779A1 (en) 1997-06-19 2002-09-26 Scil Diagnostics Gmbh Pharmaceutical compound preparation comprising a parathyroid hormone preparation and a calcium/phosphate preparation
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP1016412A4 (en) 1997-07-22 2001-05-02 Chugai Pharmaceutical Co Ltd DENTISTRY WITH PTH
KR100230578B1 (ko) 1997-07-25 1999-12-01 허영섭 포스포리불로키나제를 융합파트너로 이용하는 재조합 인간 부갑상선호르몬의 발현벡터
HU226866B1 (en) 1997-09-09 2009-12-28 Hoffmann La Roche Fracture healing using pthrp analogs
WO1999018945A1 (en) 1997-10-14 1999-04-22 Eli Lilly And Company Method of building and maintaining bone
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
EP0922467A3 (en) * 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
ID25660A (id) 1997-12-18 2000-10-19 Lilly Co Eli Teripatide kristal
SE9801495D0 (sv) 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
CA2346695A1 (en) 1998-10-07 2000-04-13 The Board Of Trustees Of The University Of Arkansas Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof
JP4486256B2 (ja) 1998-10-22 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体
US6923968B2 (en) 2000-08-10 2005-08-02 Scantibodies Laboratory, Inc. Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
WO2004028444A2 (en) 1999-06-02 2004-04-08 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
EP1222465A1 (en) 1999-09-20 2002-07-17 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
WO2001021198A1 (en) 1999-09-20 2001-03-29 Eli Lilly And Company Method for reducing the risk of cancer
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
AU7734800A (en) 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
CN100518819C (zh) 2000-06-30 2009-07-29 阿斯比奥制药株式会社 含有人甲状旁腺激素的药物成分及含有该成分的用于鼻内给药的药物组合物
US7226749B2 (en) 2000-12-05 2007-06-05 Zahradnik Richard J Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
PT1397156E (pt) 2001-06-01 2007-05-31 Novartis Ag Método para a administração oral da hormona paratireóide ( pth ).
JP4959917B2 (ja) 2001-08-17 2012-06-27 ノバルティス アーゲー 副甲状腺ホルモンフラグメント用経口送達剤としての５−ｃｎａｃ
JPWO2003024486A1 (ja) 2001-09-17 2004-12-24 中外製薬株式会社 骨量減少症治療剤
AU2002363412A1 (en) 2001-11-05 2003-05-19 Eli Lilly And Company Method for improving stability of a bone-connecting implant
EP1531855A4 (en) 2002-01-10 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA
JPWO2003064462A1 (ja) 2002-02-01 2005-05-26 中外製薬株式会社 Ｐｅｇ結合ｐｔｈ又はｐｅｇ結合ｐｔｈ誘導体
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
WO2003097690A2 (en) 2002-05-16 2003-11-27 Theratechnologies Inc. Pth derivatives resistant to skin proteases
WO2003105772A2 (en) 2002-06-13 2003-12-24 Beth Israel Deaconess Medical Center, Inc. Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
US20050032698A1 (en) 2003-07-14 2005-02-10 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
EP1651246A4 (en) 2003-08-06 2009-06-24 Innophos Inc PROCESS FOR PROMOTING BONE GROWTH
US20050119183A1 (en) 2003-11-12 2005-06-02 Nps Allelix Corp. Method for treating bone loss using parathyroid hormone
US20050215476A1 (en) 2004-01-21 2005-09-29 Unigene Laboratories Inc. Amidated parathyroid hormone fragments and uses thereof
RU2006143544A (ru) 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US20060127320A1 (en) 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052305A1 (en) 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
BRPI0509788A (pt) 2004-05-13 2007-10-23 Alza Corp aparato e método para liberação transdérmica de agentes de hormÈnio paratireóides
CN1712066A (zh) 2004-06-22 2005-12-28 中国人民解放军军事医学科学院生物工程研究所 全长人甲状旁腺激素的新用途
ITMI20041440A1 (it) 2004-07-19 2004-10-19 Abiogen Pharma Spa Peptidi analoghi del pth-1-11
US20060069021A1 (en) 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US20060089723A1 (en) 2004-10-25 2006-04-27 Murphy Kieran P Method for bone augmentation
JP2006143603A (ja) 2004-11-16 2006-06-08 Asahi Kasei Pharma Kk 骨疾患治療用医薬複合剤

Also Published As

Publication number Publication date
CN101355959B (zh) 2013-02-27
EP1945245A2 (en) 2008-07-23
IL191250A0 (en) 2009-02-11
WO2007059470A3 (en) 2007-11-22
WO2007059470A2 (en) 2007-05-24
JP2009515535A (ja) 2009-04-16
CN101355959A (zh) 2009-01-28
AU2006315132A1 (en) 2007-05-24
US20070219132A1 (en) 2007-09-20
US7994129B2 (en) 2011-08-09
CA2628945A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
MX348735B (es) Celulas madre mesenquimales que expresan los receptores tnf-alfa.
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
ATE516300T1 (de) Neuromedin-u-rezeptoragonisten und ihre verwendung
BR112017011067A2 (pt) cepas e métodos para a partição de energia em ruminantes
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
EA200600065A2 (ru) Гидрофобные композиционные и сыпучие материалы, их применение
EA200702433A1 (ru) Набухающий в воде гибридный материал с неорганическими добавками и способ его получения
MEP59208A (en) Activin-actriia antagonists and uses for promoting bone growth
CL2008000935A1 (es) Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
BRPI0516727A (pt) métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença
ECSP077222A (es) Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4)
ECSP067014A (es) Modulación de producción de inmunoglobulina y trastornos atópicos
BR0306665A (pt) Uso de zeìna nativa para aperfeiçoamento do estado do cabelo e agentes
WO2008016648A3 (en) Certain chemical entities, compositions and methods
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
NO20073033L (no) Cytotoksiske midler innbefattende nye taksaner
BRPI0507194A (pt) processo para reduzir o conteúdo e cianeto de hidrogênio em misturas compreendendo penteno-nitrilas e cianeto e hidrogênio, e, uso de 1,3-butadieno
NO20093542L (no) Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer
BRPI0408410A (pt) arranjo de um ou mais elementos estruturais para uso em uma célula de eletrólise
EA201001224A1 (ru) Химические соединения, композиции и способы их использования
EA200702092A1 (ru) Липосомная композиция для индукции иммунитета
WO2007011757A8 (en) Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
BRPI0814452A2 (pt) Composição que contém um peptídeo penetrador em células, uso de uma composição farmacêutica e método de tratamento de um tumor
BRPI0618469A2 (pt) hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.